Outsmarting Cancer: How New Technologies are Tackling a Cure
Truly the emperor of maladies, cancer remains a formidable opponent, poised to overtake cardiovascular disease as the leading cause of death in the US. It is estimated that 1 in 2 will get cancer in their lifetimes and 1 in 4 will die of the disease.
New developments, however, offer hope that we can halt or reverse these trends. An esteemed panel will discuss recent advances in genomics, big data, and machine learning that promise to deliver dramatic improvements in survival through earlier and more accurate diagnoses and better treatment choices.
White and Williams is proud to sponsor this program on the latest developments in cancer and how Fortune 500 companies, startups, nonprofits and cancer centers are all investing in the next breakthrough.
Discussion topics include:
- How new diagnostics, including gene sequencing, are uncovering the molecular signature of tumors, helping direct treatment
- How collecting and sharing real world data can similarly help reveal patterns, leading to better outcomes
- How new therapies, including cell therapy and immunotherapy, are improving cure rates across a number of tumor types
Speakers:
- Julia A. Elvin, MD, PhD | Foundation Medicine, Inc.
- Melissa Gunn | Pfizer, Inc.
- Andrew Norden, MD, MPH, MBA | IBM Watson Health, Harvard Medical School - Dana Farber Cancer Institute
- Andrew L. Pecora, MD, FACP, CPE | Physician Services Division - Hackensack Meridian Health - Regional Cancer Care Associates
- Alex K. Shalek | MIT, Ragon Institute, Broad Institute
- Jennifer L. Wong, MPP | CancrLinQ, LLC, American Society of Clinical Oncology
Additional information regarding registration available here.